GB2112640A - Process for obtaining laxative compounds from senna drug - Google Patents

Abstract

The present invention provides a process for obtaining laxative compounds from senna drug, wherein a) the senna drug is extracted with aqueous methanol by countercurrent percolation and the extract concentrated at a temperature of >/=50 DEG C. until the methanol has been completely removed from the extract; b) the extract obtained is purified by continuous liquid-liquid extraction with an organic solvent; c) the refined material (raffinate) obtained is transferred to a crystallisation apparatus, acidified, while stirring, to a pH of 1.5 to 2.0, seeded with sennoside crystals, left to crystallise while stirring and the crystalline crude sennoside obtained separated off; d) whereafter, the crude senno- dies are, if desired, recrystallised and optionally e) 10 parts by weight of the mother liquor from c) mixed, while stirring, with 2 parts by weight of sodium chloride and the semi-solid mass coagulated on the surface is decanted off, washed and optionally extracted with 95% methanol and the methanol fraction concentrated and the residue dried. n

Description

SPECIFICATION Process for obtaining laxitive compounds from senna drug The present invention is concerned with a process for obtaining laxative compounds from senna drug.

Senna drug consists of the dried leaves and pods of the senna plant, for example of Indian senna (Cassia anqustifolia) and of Egyptian senna (Cassia acutifolia). The laxative action of the senna drug is due to two classes of chemical compounds, namely, 1) the sennosides and 2) the non-sennoside laxative-active substances (hereinafter referred to as NSLAS).

The laxative-active substances in the senna drug are bimolecular glycoside derivatives of the two anthracene compounds rhein and aloe-emodin. The most important are sennosides A, B, A1, C and D. Sennosides A, B and A, are bis-glucosylrhein anthrones and sennosides C and D are glycosylrhein-glycosylaloe-emodin dianthrone compounds.

In addition to the sennosides, the crude drug also contains aglucones (sennidines) and other decomposition products and derivatives of the sennosides. Some of these can also have a laxative effect but, at the same time, can also be toxic and give rise to undesirable side effects.

Side effects which are typical for senna preparations include nausea, vomiting, wind, colic and diarrhoea.

Various processes have been described for extracting the laxative-active substances from the senna drug. The most important laxative-active glucosides, i.e. seenosides A and B, were isolated from the senna drug for the first time by Stoll et al. (see Helv. Chim. Acta, XXXII, Fasciculus VI (1949), 1892). Subsequently, many patent specifications have been published which describe processes for the preparation of sennoside concentrates.

Hitherto, the preparation of the senna extract has generally been carried out in two stages. In the first stage, vegetable pigments, fats and other impurities are removed with an appropriate solvent, for examples chloroform, ether (see U.S. Patent Specification No. 3,089,814) or with 90% methanol (see Federal Republic of Germany Patent Specification No. 1 6 1 7 667). After this preliminary extraction, the active glucosides are extracted from the drug in two stages with methanol, aqueous methanol, aqueous ethanol or only with water.

In order to facilitate the extraction, the methanol used can be rendered alkaline by the addition of organic bases (see Federal Republic of Germany Patent Specification No. 23 397).

The organic bases form methanol-soluble salts with the sennosides which can easily be extracted. However, a disadvantage of this process is that the extract contains a high content of impurities.

It has also been suggested to use extraction solvents acidified with citric acid (see French Patent Specification No. M 6611 (1969)) or with oxalic acid (see British Patent Specification No.

832,017). In the latter case, 70% ethanol was used as solvent. If acidic methanol or acidic aqueous methanol is used for the extraction, the content of impurities in the extract is smaller than when the extraction is carried out with basic solvents or with water alone. However, this process has the disadvantage that the sennosides, which are acidic compounds, are, as free acids, only sparingly soluble in the solvents used. Consequently, the amount of solvent required for the extraction is very large and can be as much as 1 5 to 20 times of the weight of the drug used.

For the extraction of the drug, it is also known to use mixtures of methanol-tetrahydrofuran, methanol-dioxan and tetrahydrofuran-dioxan acidified with phosphoric acid (see Hung. Teljes, 6006 (1973)) and aqueous phosphoric acid (see Federal Republic of Germany Patent Specification No. 1 6 1 7 667) as solvents. However, these solvents activate the glucosidase enzyme so that some of the active glucoside is hydrolysed, especially when using weakly acidic solution, the pH value of which corresponds to that of the original plant material. This results in a reduction of the amount of active material in the extract (see also Federal Republic of Germany Patent Specification No. 29 15063).

According to the prior art, the sennoside concentrate is obtained from the extracts in various ways.

A solid, sennoside-containing extract is obtained by gentle drying of the extract (see Federal Republic of Germany Patent Specification No. 1 6 1 7 667). The product then contains all the substances present in the extract, the sennoside content of the product being about 17 to 18%.

However, the sennosides can be separated more selectively when they are precipitated from aqueous solutions by the addition of organic solvents. The product obtained contains less ballast materials and has a sennoside content of 60 to 70%. The precipitation can be carried out by the addition of diethyl ether (see French Patent Specification No. M 611; Magyar G. et al., Hung.

Teljes, 6006 (1973)), isopropyl alcohol, after treatment with a strongly acid ion exchange resin (see British Patent Specification No. 832,017) or ethanol (see Finnish Patent Specification No.

41588). The sennosides in solution can possibly be conveted into the calcium salts (see U.S.

Patent Specification No. 3,089,814 and Finnish Patent Specification No. 41588) and subse quently precipitated out by the addition of organic solvents so that the active glucosides are obtained as calcium salts. The content of sennosides in the precipitated product then amounts to about 60 to 70%.

For obtaining pure sennosides as free acids, the sennosides are isolated as calcium salts and these salts then decomposed with oxaiic acid (see Stoll et al., Heiv. Chim. Acta, XXXII, Fasciculus VI (1949), 1892).

Thus, according to these known processes, extracts and various kinds of concentrates containing laxative-active substances can be produced from the senna drug. The amount of laxative-active substances in the concentrates depends upon the content of these substances in the original drug and upon the production process used. One difficulty in the standardisation of the senna preparations is the determination of the senna glycosides. The drug contains various compounds which are included in the determination of the senna glycosides. However, the physiological action of these individual compounds is not the same.Since, with the help of conventional methods of determination, it is not possible to differentiate the senna glycosides from the other compounds which have different physiological actions and possibly side reactions, it is difficult to produce preparations, starting from conventional senna extracts, which always produce the same and reproducible action with the same dose.

It is an object of the present invention to provide a process for obtaining laxative compounds from the senna drug which permits the laxative-active substances to be obtained in improved yield in the most concentrated form as possible, which are as free as possible from components with undesired side effects.

Thus, according to the present invention, there is provided a process for obtaining laxative compounds from senna drug, wherein a) the senna drug is extracted with aqueous methanol by countercurrent percolation and the extract concentrated at a temperature of '50 C. until the methanol has been completely removed from the extract; b) the extract obtained is purified by continuous liquid-liquid extraction with an organic solvent; c) the refined material (raffinate) obtained is transferred to a crystallisation apparatus, acidified, while stirring, to a pH of about 1.5 to 2.0, seeded with sennoside crystals, left to crystallise while stirring and the crystalline crude sennosides obtained separated off;; d) whereafter the crude sennosides are, if desired, recrystallised and optionally e) 10 parts by weight of the mother liquor from stage c) mixed, while stirring, with 2 parts by weight of sodium chloride and the semi-solid mass coagulated on the surface is decanted off, washed and optionally extracted with 95% methanol and the methanol fraction concentrated and the residue dried.

For carrying out the process according to the present invention, mixtures of methanol and water are used in which the sennosides are soluble. It is preferable to use 70% methanol since the maximum solubility of the sennosides lies at a methanol concentration of 60 to 70%. The extraction is carried out in portions and preferably at a slightly elevated temperature but at most at a solvent temperature of + 35"C. Since there is a danger that the sennosides would decompose, elevated temperatures have previously been avoided. However, we have, surprisingly, found that the sennosides do not decompose at a slightly elevated temperature when methanol is used as solvent.

The drug extraction is carried out in a countercurrent percolation plant. In general, 2 to 4 percolators are used. If the extraction solvent is to be warmed, it is allowed to circulate through an external heat exchanger in which it is thereby warmed to the desired temperature but at most to 35'C. The more percolators are used, the less must the solvent be warmed. The extract obtained then contains less harmful impurities and the sennosides crystallise out completely from the mother liquor.

Before the extraction, it is preferable to swell the dry drug in a solvent, for which purpose it is preferable to use the post-percolate from a previously extracted drug. For this purpose, the dry drug is placed in a percolator, covered with a perforated plate with a weight of about 0.7 kg./dm2 and the solvent or post-percolate passed in. The weight of the amount of solvent required is about three times the weight of the dry drug. It is preferably left to stand overnight and the extraction is commenced the next day.

The extraction takes place over the course of 1 6 to 20 hours, during which time the necessary amount of 70% methanol is allowed to flow through the dry mass. Since it is preferable to use several percolators, when carrying out the extraction the solvent is first passed into the percolator of the series of percolators which contains the weakest drug, i.e. the one which has already been most extracted and which is to be the next one to be emptied. The solvent is passed from this percolator to the next percolator and so forth. The main extract is taken from the percolator which was the last one to be filled. After removal of an appropriate amount of extract, thee is additionally obtained a post-percolate which can be used for swelling a new batch of dry drug.For this purpose, the percolator containing.the weakest drug is--L -- emptied, filled with a quantity of drug, the post-percolate passed in and the extraction carried out on the next day.

According to the process of the present invention, it is possible to extract 1 part of the dry drug with only 4 parts of extraction solvent. If 70% methanol is used at ambient temperature, then the residual amount of substance in the drug is about 41 % per percolator in the series of percolators. With two percolators, the extraction yield is (1 - 0.412) x 100 = 83% and with three percolators connected in series it is (1 - 0.413) x 100 = 93%.

After the extraction, the methanol is removed practically quantitatively from the percolate, the volume of the bottom product obtained being about one fifth of the volume of the percolate.

The methanol is removed with the use of a vacum distillation apparatus equipped with a fractionation column. Because of the danger of hydrolysis of the sennosides, the temperature must not exceed + 50"C.

The concentrate obtained contains, in addition to the sennosides, all products which can be extracted with methanol from the original plant material. The concentrate is preferably mixed with about 5% butan-2-ol in order to keep the fats in the concentrate in emulsion and also to act as a preservative so that the growth of micro-organisms and putrefaction of the solution caused thereby are inhibited.

Afer distilling off the methanol, the concentrate is purified by liquid-liquid extraction with an organic solvent. The solvent used can be an alcohol or ketone which is partly soluble in water, for example, butanol, methyl ethyl ketone or methyl isopropyl ketone, the preferred solvent being butan-2-ol. The liquid-liquid extraction is carried out as a continuous process in a partitioning apparatus with a separation effect of about 10 theoretical steps. The pH of the fedin concentrate solution is thereby about 5.4 to 5.6 since, at this pH, the salts of the aglucone compounds present in the senna drug are hydrolysed to such an extent that the aglucones are removed practically quantitatively from the raffinate.

Before use, the butan-2-ol employed for the extraction is preferably saturated with water. The fed-in concentrate which is to be extracted is a very concentrated solution with a content of dry material of about 20 to 30%. It contains salts, sugars, amino acids and other water-soluble compounds which originate from the plant mass. The extraction is preferably carried out in such a manner that the run-off ratio of butan-2-ol: raffinate is about 0.7 to 0.8:1.

By means of the liquid-liquid extraction, fats, harmful plant pigments, chlorophylls and carotinoids, free fatty acids, steriods, agluconic anthracene derivatives, neutral glucosides, vegetable waxes and wax alcohols, flavones and other phenols, etc. are removed from the solution. In this way, the raffinate obtained is freed from harmful impurities to such an extent that the main amount of the sennosides can be crystallized out directly from the raffinate phase by acidification with a mineral acid to a pH of about 1.2 to 2.0, the mineral acid used preferably being hydrochloric or sulphuric acid.

In order to crystallise the sennosides from the raffinate phase, this is placed in a container and an amount of acid is passed in while stirring, until the pH value of the solution is about 1.5 to 2.0. The solution is then seeded with sennoside crystals and left to crystallise for 1 week, while stirring.

On the other hand, the crystrallisation can also be carried out in a continuously operating crystallisation apparatus. The raffinate phase thereby remains for about 1 week in this crystallisation apparatus and is thereby divided between 2 or more containers connected in series which discharge into a decanter. The crystallisation containers are continuously gently stirred and, for acidification, a solution of the mineral acid is introduced, with stirring, into the first container. The vertical laminar flow in the containers is about 0.3 to 0.4 mm./minute. This rate of flow ensures a satisfactory sedimentation. The crystallised product is filtered off, washed with water and methanol or acetone and then dried. If desired, the crude product is recrystallised, as is explained hereinafter.

A fraction of the senna drug which is important with regard to the biological actions is the fraction containing the non-sennoside laxative-active substances (NSLAS). This fraction occurs in varying amounts in crude drugs, extracts and senna preparations. In addition, these substances are formed during the drug extraction. The laxative activity of the crude NSLAS fraction amounts to about 60% of the laxative activity of the mixture of pure sennosides. However, the intravenous toxicity of the crude NSLAS fraction amounts to about 20 times the toxicity of the mixture of the pure sennosides. The chemical properties of the NSLAS fraction, its solubility in various solvents, the partition properties and the behaviour in the case of salt formation remind one of the corresponding properties of the sennosides.

The NSLAS fraction contains the residues of the sennosides which remain in the mother liquor in the case of the crystallisation of the raffinate phase after the purification extraction with the organic solvent. The sennoside content of the crude NSLAS fraction amounts to 5 to 10%. This fraction thereby contains 5 to 10% of rhein-8-glucoside and 80 to 90% of compounds, the chemical structure and physilogical actions of which are hitherto unknown. The crude NSLAS fraction can be divided into approximately two equally large fractions by leaching out with 95% methanol. The portion which is insoluble in 95% methanol is a brown powder. This hitherto unknown compound chromatographs in the case of gel chromatography like homogeneus compound and has a retention volume which corresponds to a molecular weight of from 1000 to 10,000.The portion of the NSLAS fraction which is soluble in 95% methanol consists of compounds with low molecular weights. This fraction contains abut 20% of sennosides. The main portion of this fraction consists of compounds which have not previously been identified in the senna drug or are completely unknown.

The crude NSLAS fraction can be readily separated when the mother liquor of the sennosides is mixed with a salt, for example sodium chloride. For this purpose, after filtering off the sennosides, 2 parts by weight of solid sodium chloride are gradually added, with continuous stirring, to 10 parts of the mother liquor and stirring is continued for 1 to 2 hours.

Subsequently, the semi-solid mass which has coaguated on the surface of the solid is decanted off from the solution, washed by suspending in water, the suspension is stirred overnight and the precipitate allowed to settle out the next day, whereafter the bulk of the wash solution is decanted off. The precipitate is filtered off with a suction filter or with a filtration centrifuge, washed with water and anhydrous methanol and dried in a current of air at ambient temperature. When senna pods are used as raw material, the yield of crude NSLAS fraction is about 1.5 to 1.6% of the weight of raw material used. The precipitation by salting out can also be carried out from a dilute solution.

The crude sennosides obtained after the crystallisation can, if desired, be recrystallised. For this purpose, the crude sennosides are suspended in a mixture of acetone and water (50:50) to give an approximately 10% suspension, dissolved by the addition of sodium hydroxide to a pH of about 7.5 to 9, with sodium salt formation and the sennosides again precipitated out by adjusting the solution with hydrochloric acid to a pH of about 1.5 to 2, separated off, washed with aqueous acetone and dried.

According to the present invention, the laxative-active compounds contained in the senna drug can be divided into two fractions, namely, into a sennoside fraction and into an NSLAS fraction. The latter fraction can be divided into two further fractions, namely, into a "resin" and into a low molecular weight fraction. The laxative activity of all fractions accounts for about 90% of the total laxative activity of the senna drug.The values for the laxative activity and the intravenous toxicity of the fractions, which were determined by experiments on mice, are given in the following Table: TABLE crude NSLAS fraction sennoside 95% methanol- "resin" property fraction soluble fraction fraction laxative action 100 100 < 10 LD50i.v.mg./kg. 4100 4100 130 Thus, with the process according to the present invention, it is possible to obtain the sennosides in almost 100% purity from the crude drug. Furthermore, it is also possible to isolate the NSLAS crude fraction in a concentrated form from the mother liquors of the sennosides. In addition, in the case of the process according to the present invention for obtaining laxative-active substances from senna drug, a preliminary extraction of the drug is no longer required, as is necessary in the case of the previously known processes.

Since the sennosides obtained by the process according to the present invention are chemically and pharmacologically completely characterised, they can be used for the formuation of medicinal compositions with definite galenical properties. In contradistinction thereto, according to the previously known processes, only more or less indefinite galenical extracts can be obtained.

The present invention also provides laxative compositions containing at least one laxative compound obtained by the process of the present invention, in admixture with a solid or liquid pharmaceutical diluent or carrier.

The following Examples are given for the purpose of illustrating the present invention: Example 1.

40 kg. amounts of senna drug are placed into two series-connected percolators with a volume of 250 litres which are covered with perforated steel plates. The solvent used for the extraction is 70% methanol which is supplied to the drug in the first percolator. A bottom plate covered with a filer cloth is present on the bottom of the percolator. By means of an emptying cock provided below this plate, the solution is passed to the drug present in the second percolator, the solvent thereby being allowed to flow freely through the first percolator. The rate of flow of the solvent is adjusted by means of the emptying cock on the first percolator. The run-off on the second percolator is adjusted in such a manner that the level of the solvent in the second percolator is high enough to cover the perforated steel plate, which has a weight of 0.7 kg./dm2.

For the extraction of 40 kg. of senna drug, a total of 1 60 litres of solvent are used. After this amount of 70% methanol has passed through both percolators and an appropriate amount of percolate has been collected, the emptying pipe of the percolator is connected to a postpercolate container and an additional 60 litres of 70% methanol are passed through the percolators. Thereafter, residual free solvent is passed from the first percolator into the upper part of the second percolator and the post-percolate is collected until a total of 1 20 litres have been obtained. The first percolator is then emptied, again filled with 40 kg. senna drug and the post-percolate is pumped on to the drug, 1 20 litres of post-percolate being sufficient to cover the drug in the percolate.Subsequently, a piped connection is made from the run-off to a pump and a heat exchanger and from there to the cover of the percolator and the solution is allowed to circulate until the temperature of the solution is + 30"C. It is then left to stand overnight.

The following day, this percolator is connected to the one previously extracted and the extraction carried out in the above-described manner.

For each 40 kg. of drug there are collected 1 60 litres of percolate from which the methanol is removed in a vacuum rotary evaporator equipped with a packed column. About 30 litres of bottom product are obtained which is extracted in the "mixer-settler" apparatus (10 stage) using 40 litres of water-saturated butan-2-ol. About 38 to 40 litres of aqueous raffinate are obtained and about 30 to 32 litres of butan-2-ol extract. The aqueous raffinate is acidified with 93% sulphuric acid, while stirring, during the course of 20 hours, 1.6% by volume (referred to the volume of liquid to be acidified) thereby being used. The acidified solution then has a pH of 1.5 to 2.0.After stirring for a further 6 days, the precipitate is allowed to deposit overnight, filtered, washed with water until the wash water is colourless, washed with methanol and dried in a current of air at ambient temperature. The yield per 40 kg. of raw material is 760 to 790 g.

(dry substance) with a sennoside content of 90 to 94%. Thus, the yield is about 70% of the amount of sennoside present in the raw material.

0.5 kg. of crude product is suspended in 5 litres of an acetone-water mixture (1:1 v/v), 48% aqueous sodium hydroxide are added thereto, while stirring, until the pH of the solution is 8.5 to 9. Insoluble residue is filtered off and 35% hydrochloric acid is added to the filtrate until the pH of the solution is 1.5 to 2. Stirring is continued until crystallisation commences and then the solution is left to crystallise for at least 3 hours. The precipitate is filtered off from the solution, washed on the filter with 0.5 litre of water and 0.5 litre of acetone and dried at ambient temperature with a current of air. One fifth of the mother liquor can be mixed with wash water and wash acetone and this solution used as crystallisation solvent for the next equally large portion of crude product.The yield per 0.5 kg. of crude product is 0.460 kg. (dry substance) with a sennoside content of 98 to 99%.

Example 2.

The procedure described in Example 1 is employed but using three series-connected percolators and without warming the 70% methanol. Otherwise the procedure is as described in Example 1, using 1 60 litres of solvent per 40 kg. of drug. From 40 kg. of drug there is obtained 0.890 kg. of sennoside crude product with a sennoside content of 92% (dry substance). The crude product can be recrystallised as in Example 1.

Example 3.

Extraction, removal of methanol from the extract and liquid-liquid extraction are carried out as described in Example 1. After the treatment with butan-2-ol, the sennoside mixture is crystallised from the raffinate in a continously-operating crystallisation apparatus. For the crystallisation, use is made of two containers, connected one after the other, and a third container as decanter, which is connected in series to the others. Sedimentation of the sennoside mixture is carried out in the latter container, the main amount of the precipitate thereby being separated from the mother liquor. For this purpose, the raffinate phase obtained after the purification with butan-2-ol is passed at a rate of about 2 litres/hour into the first container. 93% Sulphuric acid is simultaneously pumped, in an amount of 1.6% by volume of the raddinate, into this container.In order to prevent sedimentation at this point, the liquid in the first container is stirred continuously. The suspension from the first container is then passed via an unrestricted overflow into the second container, which is also equipped with a stirrer, and from there, via an unrestricted overflow, into the third container, where the precipitate is allowed to settle, the mother liquor being allowed to run off via an unrestricted overflow to a waste solvent container. The precipitate is removed from the third decanter, through a cock provided on the bottom thereof, in the form of a thick suspension which is filtered with a suction filter, washed with water and methanol and dried in a current of air at ambient temperature. The yield per 40 kg. of crude material used is 790 g., the sennoside content of which is 91%.

Example 4.

The mother liquor of Example 1 (obtained after the crystallisation from the aqueous raffinate) is treated with sodium chloride. For this purpose, 40 litres of mother liquor (corresponding to 40 kg. of originally used raw material) are gradually mixed, while stirring, with 8 kg. of sodium chloride. A brownish, semi-solid precipitate is thereby obtained. Stirring is continued for 2 hours and the precipitate is macerated in the solution until the next day. The mother liquor is then decanted off from the precipitate, the precipitate is suspended in 40 litres of water, the suspension is stirred for 20 hours and the precipitate allowed to settle out. The precipitate is then filtered off with a suction filter, washed with a copious amount of water, dried at ambient temperature in a current of air and the dried substance passed through a 0.5 mm. mesh sieve.

The yield is 0.60 kg.

The high pressure liquid chromatography (HPLC) analysis shows that the precipitate contains about 5% of sennosides and also 5% of rhein-8-glucoside. The laxative activity of this material is about 58% of the laxative activity of the sennosides. The toxicity, determined by intravenous administration is LD50 = 430 mg./kg. (mouse). Thus, this fraction contains unknown compounds which, on the one hand, have a laxative activity but, on the other hand, possess a greater toxicity than the sennosides. The laxative activity of this non-sennoside fraction accounts for about 40% of the total laxative activity of the original drug and of the crude extract.

48 g. of the crude NSLAS fraction are leached out 12 times with 500 ml. amounts of 95% methanol. For this purpose, the ground powder is stirred with each portion of 95% methanol for at least 2 hours. The methanol wash fractions are combined and evaporated to dryness. The weight of the residue obtained is 22 g. Its laxative activity is the same as in the case of the pure sennosides and its toxicity is LD50 i.v. = 4100 mg./kg. (mouse). The resinous portion, which is insoluble in 95% methanol, is dried, the yield being 20.8 g. The laxative activity is less than 10% of the laxative activity of the sennosides and the toxicity is LD50 i.v. = 1 30 mg./kg.Thus, the NSLAS fraction isolated from the mother liquor of the sennosides by salting out contains laxative-active, non-toxic compounds of unknown chemical structure which are soluble in 95% methanol and a very toxic resinous portion which has only a low laxative activity and the chemical structure of which is also unknown.

Example 5.

The extraction, liquid-liquid extraction and recrystallisation described in the following are illustrated schematically in Figs. 1, 2 and 3 of the accompanying drawings.

The drug is extracted at ambient temperature in a 4-stage countercurrent percolation plant.

For this purpose, 40 kg. of senna pods are introduced daily into one of four conical containers and weighed down with a perforated plate.

70% Methanol is passed in countercurrent through the battery of 4 percolators in an amount such that the freshly introduced pods are completely covered with liquid. After a maceration period of at least 1 2 hours, percolation is continued until a total of about 1 60 litres of 70% methanol have passed through. From the container covered with fresh solvent, the extraction liquid is then passed completely into the next container connected in series and the extraction residue dried in order to recover the solvent. The container is now ready to receive the next 40 kg. batch of drug and this is switched over to the end of the battery. The degree of efficiency of the extraction per percolation stage is about 60%.From each 40 kg. of senna pods, there are obtained about 1 20 litres of primary extract which are concentrated to about 30 litres under vacuum in a rotary evaporator equipped with a fractionating column. The temperature in the product container must thereby not exceed 50"C.

In order to keep the following liquid-liquid extraction free from disturbance, the methanol must be completely removed. After ascertaining gas chromatographically that the concentrate is free from methanol, it is subsequently mixed with about 2% of butan-2-ol. The pH value of this extract is about 5.8.

For the subsequent liquid-liquid extraction, the concentrate is passed in a 10-stage mixerseparator battery (each stage about 5 litres), without previous filtration, counter to butan-2-ol. In the case of a run-in rate of butan-2-ol: extract concentrate of 1.5:1, the ratio of butan-2-ol extract: extract raffinate is 0.7 to 0.8:1. The average residence time for each stage is about 20 minutes.

The extract reffinate is then adjusted with 94% sulphuric acid to a pH of 2 and passed to a 3stage crystallisation apparatus.

To intiate the crystallisation, it is seeded and then left to crystallise at ambient temperature for 5 days. The crystal slurry obtained is removed from the bottom of the third crystallisation container. The withdrawn crystal slurry is suction filtered and the mother liquor returned to the crystallisation apparatus. The crystals are subsequently washed with water and then with methanol and dried in a vacuum at 40"C. Crude sennosides are obtained with a degree of purity of about 90%. For recovering the butan-2-ol, the butan-2-ol extract is completely evaporated, a dark brown to black residue being obtained. The distillate is again used for the liquid-liquid extraction.

The crude sennosides obtained are then suspended in an acetone-water mixture (50/50) to give a 10% suspension and completely dissolved by the addition of an aqueous solution of sodium hydroxide until the pH is about 7.5, sodium salt formation thereby taking place. The sennosides are then precipitated out again by adjusting the pH of the solution to 2 with hydrochloric acid. The precipitated product is separated off, briefly washed with aqueous acetone and dried. In this way, there are obtained about 2% (referred to the senna pods used) of pure sennosides (A and B).

Claims (14)

1. Process for obtaining laxative compounds from senna drug, wherein a) the senna drug is extracted with aqueous methanol by countercurrent percolation and the extract concentrated at a temperature of (50"C. until the methanol has been completely removed from the extract; b) the extract obtained is purified by continuous liquid-liquid extraction with an organic solvent; c) the refined material (raffinate) obtained is transferred to a crystallisation apparatus, acidified, while stirring, to a pH of 1.5 to 2.0, seeded with sennoside crystals, left to crystallise while stirring and the crystalline crude sennosides obtained separated off;; d) whereafter the crude sennosides are, if desired, recrystallised and optionally e) 10 parts by weight of the mother liquor from c) mixed, while stirring, with 2 parts by weight of sodium chloride and the semi-solid mass coaguated on the surface is decanted off, washed and optionally extracted with 95% methanol and the methanol fraction concentrated and the residue dried.

2. Process according to claim 1, wherein 70% methanol is used as extraction solvent in stage a).

3. Process according to claim 1 or 2, wherein the extraction in stage a) is carried out at an elevated temperature of at most 35"C.

4. Process according to any of the preceding claims, wherein the countercurrent percolation is carried out in a battery of 2 to 4 percolators connected in series.

5. Process according to any of the preceding claims, wherein the senna drug is swollen in a post-percolate before the percolation.

6. Process according to any of the preceding claims, wherein the concentrate obtained in stage a) is mixed with about 5% butan-2-ol.

7. Process according to any of the preceding claims, wherein the organic solvent used in stage b) is butanol, methyl ethyl ketone or methyl isopropyl ketone

8. Process according to claim 7, wherein the organic solvent used is butan-2-ol saturated with water.

9. Process according to claim 8, wherein the run-off ratio of butan-2-ol:raffinate is 0.7 to 0.8:1.

10. Process according to any of the preceding claims, wherein acidification in stage c) is carried out with hydrochloric acid or sulphuric acid.

11. Process according to any of the preceding claims, wherein the crude senosides obtained in stage c) are, for recrytallisation, suspended in an acetone-water mixture (50/50) to give an approximately 10% suspension, which is completely dissolved by adding sodium hydroxide until the pH is 7.5 to 9, with the formation of sodium salts, whereafter the sennosides are again precipitated out by adjusting the solution with hydrochloric acid to a pH of about 1.5 to 2, separated off, washed with aqueous acetone and dried.

1 2. Process according to claim 1 for obtaining laxative compounds from senna drug, substantially as hereinbefore described and exemplified.

1 3. Laxative compounds, whenever obtained from senna drug by the process according to any of claims 1 to 12.

14. Laxative compositions, containing at least one laxative compound according to claim 13, in admixture with a solid or liquid pharmaceutical diluent or carrier.